PET/MRI assesses ankylosing spondylitis treatment

Thursday, December 2 | 9:30 a.m.-10:00 a.m. | SSNMMI07-4 | Room E450B
F-18 sodium fluoride PET/MRI (F-18 NaF PET/MRI) of osteoblastic activity in ankylosing spondylitis patients can assess the effects of anti-tumor necrosis factor (TNF) therapy, according to German researchers presenting in this session.

Diagnostic and interventional radiologist Dr. Nils-Martin Bruckmann of the University of Dusseldorf will discuss details of a study in 11 men and five women with clinically active radiographic axial spondyloarthritis (r-axSpA). The researchers performed F-18 NaF PET/MRI scans of the sacroiliac joint and whole spine in patients at baseline and at time points up to six months following anti-TNF therapy.

Three independent readers evaluated all images for inflammation (bone marrow edema) and structural lesions. F-18 NaF uptake was recorded on the level of sacroiliac joint quadrants (SIJ-Q) and vertebral quadrants (VQ). The researchers analyzed a total of 128 SIJ-Qs and 920 VQs at each time point.

At baseline, F-18 NaF uptake was found in 96% of sacroiliac joint quadrants with bone marrow edema, 94.2% of quadrants with sclerosis, and 88.3% with fat lesions. At follow-up, there was a significant decrease in F-18 NaF uptake, with uptake in 65.3% of sacroiliac joint quadrants with bone marrow edema, 33.8% with sclerosis, and 24.5% with fat lesions.

The findings support the early initiation of anti-inflammatory treatment for the prevention of radiographic progression in axial spondyloarthritis, the group noted.

Find out more about the study by attending this session on Thursday morning.

Page 1 of 436
Next Page